{"filings":[{"id":2144239,"accession_number":"0001193125-26-341206","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-08-10T11:05:20+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome Q2 2026 revenue up 46% to $218.4M; AUVELITY Alzheimer's launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $218.4M, +46% YoY; AUVELITY sales $180.3M (+51% YoY), SUNOSI $35.8M (+20%), SYMBRAVO $2.3M (+461%).","Net loss $51.3M ($0.99/share) vs $48.0M loss ($0.97) in Q2 2025; SG&A up to $208.1M from $130.3M on launch activities.","AUVELITY launched for Alzheimer's disease agitation in June 2026; new-to-brand Rx +126% in patients ≥65 in first 8 weeks.","NDA for AXS-12 (cataplexy in narcolepsy) accepted by FDA; PDUFA target action date May 1, 2027.","Cash $319.9M at June 30, 2026; guidance says sufficient to fund operations into cash flow positivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1646357,"accession_number":"0001193125-26-304039","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-07-15T11:05:15+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Axsome's NDA for AXS-12 (reboxetine) for cataplexy in narcolepsy; PDUFA May 1, 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted for filing Axsome's New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy.","PDUFA target action date set for May 1, 2027.","FDA indicated it does not currently plan to hold an advisory committee meeting for the application.","Axsome Therapeutics (AXSM) announced the acceptance on July 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":947956,"accession_number":"0001193125-26-264047","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-06-09T21:20:47+00:00","items":["5.02","9.01"],"status":"ready","headline":"Axsome adopts Executive Severance Plan with CIC benefits for officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan effective June 5, 2026, covers CEO (Tier 1), other Section 16 execs (Tier 2), and VPs+ (Tier 3).","Outside CIC: CEO gets 18 months base salary plus 18 months COBRA; Tier 2 gets 12 months base plus COBRA.","Inside CIC: CEO gets 24 months base plus target bonus, 24 months COBRA, and full equity vesting.","Tier 2 inside CIC: 18 months base plus bonus, 18 months COBRA, full equity vesting; Tier 3: 9 months package."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":947958,"accession_number":"0001193125-26-264043","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-06-09T21:19:56+00:00","items":["5.07","9.01"],"status":"ready","headline":"Axsome shareholders elect directors, ratify Deloitte, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Mark Saad elected Class II director with 28,675,654 votes for, 10,286,822 withheld.","Susan Mahony elected Class II director with 29,892,131 votes for, 9,070,345 withheld.","Ratification of Deloitte & Touche as auditor passed with 43,278,147 votes for (98.9% of votes cast).","Non-binding advisory vote on executive compensation approved with 37,818,384 votes for (97.5% of votes cast).","Approximately 85.1% of outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":816516,"accession_number":"0001193125-26-254708","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-06-03T13:04:18+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome settles all SUNOSI patent litigation; generic entry deferred to 2040","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Resolved all outstanding SUNOSI patent litigation with the last first-to-file generic applicant.","Settlement grants five companies right to sell generic SUNOSI starting September 1, 2040 (if pediatric exclusivity) or March 1, 2040.","No other patent litigation remains for SUNOSI.","Settlement will be submitted to FTC and DOJ for review as required by law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93817,"accession_number":"0001193125-26-202506","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome Q1 revenue $191.2M (+57% YoY); Auvelity approved for Alzheimer's agitation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $191.2M (+57% YoY); Auvelity $153.2M (+59%), Sunosi $33.9M (+34%), Symbravo $4.1M.","Net loss $64.5M ($1.26/share) vs $59.4M ($1.22/share) YoY; cash $305.1M at March 31, 2026.","FDA approved Auvelity for agitation in Alzheimer's disease (April 2026); full commercial launch expected June 2026.","NDA submitted for AXS-12 (cataplexy in narcolepsy); pipeline expanded with AXS-20 (balipodect) for schizophrenia/Tourette.","Cash guidance: current resources sufficient to fund operations into cash flow positivity."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":191203000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93816,"accession_number":"0001193125-26-197857","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome Therapeutics announces FDA approval of AUVELITY for Alzheimer's disease agitation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["AUVELITY (dextromethorphan HBr/bupropion HCl) approved for agitation associated with dementia due to Alzheimer's disease.","First-in-class NMDA/sigma-1 receptor-targeted treatment; supported by Phase 3 ADVANCE-1 and ACCORD-2 trials.","In ADVANCE-1, AUVELITY showed statistically significant improvement vs placebo on CMAI at Week 5 (primary endpoint).","In ACCORD-2, AUVELITY significantly delayed time to relapse vs placebo (up to 6-month double-blind phase).","Safety profile: 1.3% discontinuation due to adverse events (same as placebo); common side effects: dizziness, dyspepsia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93815,"accession_number":"0001193125-26-135669","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome acquires global rights to PDE10A inhibitor balipodect from Takeda","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Obtained exclusive worldwide rights to balipodect, a selective PDE10A inhibitor, from Takeda.","Balipodect completed a 164-patient Phase 2 trial in schizophrenia; safety profile established in over 360 individuals.","Axsome plans to start Phase 3-enabling activities for schizophrenia in 2026 and also target Tourette syndrome.","Takeda received an upfront payment and is eligible for development, regulatory, and commercial milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105743,"accession_number":"0001193125-26-062421","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Axsome Q4 revenue $196M (+65% YoY); AXS-05 PDUFA set for April 30, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue Q4 $196.0M, FY $638.5M (+66% YoY); AUVELITY sales $507.1M (+74%).","Net loss Q4 $28.6M ($0.56/share), FY $183.2M ($3.68); cash $322.9M; operating loss narrowed.","sNDA for AXS-05 (Alzheimer's agitation) granted Priority Review, PDUFA target April 30, 2026.","SUNOSI generic patent litigation with Alkem settled; license delays generic entry until 2040.","Acquired AXS-17 (GABA A PAM) for epilepsy; NDA submission for AXS-12 narcolepsy expected Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":638496000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105742,"accession_number":"0001193125-26-053009","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome settles SUNOSI patent litigation; generic entry delayed to 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alkem can sell generic SUNOSI on/after March 1, 2040 (no pediatric exclusivity) or September 1, 2040 (if granted), subject to FDA approval.","Settlement resolves Alkem's ANDA patent litigation in District of New Jersey; similar litigation with another party remains pending.","Agreement submitted to FTC and DOJ for review as required by law.","No financial terms disclosed in the settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105741,"accession_number":"0001193125-26-009744","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome reports preliminary 4Q and FY 2025 net product revenue of $196M and $638.5M, up 65% and 66% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total preliminary 4Q net product revenue $196.0M (+65% YoY); full year $638.5M (+66% YoY).","AUVELITY net product sales: $155.1M (4Q), $507.1M (FY).","SUNOSI net product revenue: $36.7M (4Q), $124.8M (FY).","SYMBRAVO net product sales (launched June 2025): $4.1M (4Q), $6.6M (FY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":638496000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122027,"accession_number":"0001193125-25-337644","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Priority Review to AXS-05 for Alzheimer's agitation; pre-NDA meeting supports AXS-12 narcolepsy filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted sNDA for AXS-05 (dextromethorphan/bupropion) for Alzheimer's agitation; Priority Review with PDUFA date April 30, 2026.","Pre-NDA meeting minutes confirm data package sufficient for AXS-12 (reboxetine) in narcolepsy cataplexy; NDA submission expected January 2026.","AXS-12 has Orphan Drug Designation for narcolepsy, potentially providing 7 years US exclusivity if approved.","AXS-05 previously received Breakthrough Therapy designation for Alzheimer's agitation (June 2020)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122026,"accession_number":"0001193125-25-261651","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome Q3 2025 net product revenue $171M, up 63% YoY; submits sNDA for AXS-05 in Alzheimer's agitation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $171.0M (63% YoY growth); AUVELITY $136.1M (+69%), SUNOSI $32.8M (+35%), SYMBRAVO $2.1M (first full quarter).","Net loss narrowed to $47.2M ($0.94/share) from $64.6M ($1.34/share) in Q3 2024; cash $325.3M.","Submitted sNDA for AXS-05 in Alzheimer's disease agitation (FDA Breakthrough Therapy); plans NDA submission for AXS-12 in narcolepsy in Q4 2025.","Pipeline: Phase 3 trials to initiate in Q4 2025 for AXS-05 (smoking cessation), solriamfetol (pediatric ADHD, MDD+EDS), and AXS-14 (fibromyalgia).","AUVELITY prescriptions ~209k in Q3 (+46% YoY); contracted with third large GPO; payer coverage ~85%."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":442497000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138738,"accession_number":"0001579428-25-000007","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome receives ANDA Paragraph IV notice from Apotex for generic Symbravo","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Apotex filed an ANDA seeking FDA approval to market a generic version of Symbravo (meloxicam-rizatriptan benzoate).","Paragraph IV certification notice received August 19, 2025; Axsame plans to respond in due course.","If Axsame sues within 45 days, a 30-month stay could delay generic approval.","Generic competition threatens Symbravo revenue, which is Axsome's key commercial product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138737,"accession_number":"0000950170-25-101624","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome Q2 product revenue $150M (+72% YoY); AUVELITY sales $119.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $150.0M, up 72% YoY and 24% sequentially.","AUVELITY net sales $119.6M (+84% YoY); ~192k prescriptions written in Q2.","Net loss narrowed to $48.0M ($0.97/share) from $79.3M ($1.67/share) in Q2 2024.","Cash $303.0M; management says sufficient to fund operations into cash flow positivity.","Pipeline: sNDA for AXS-05 in Alzheimer's agitation on track for Q3 2025; NDA for AXS-12 in narcolepsy expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":271505000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156185,"accession_number":"0000950170-25-084098","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome launches SYMBRAVO for acute migraine treatment in U.S.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SYMBRAVO (meloxicam/rizatriptan) now available by prescription for acute migraine with or without aura in adults.","Novel multi-mechanistic approach targeting multiple migraine pathways; rapid pain freedom at 2 hours vs placebo, sustained up to 24 hours.","Axsome launches SYMBRAVO On My Side patient support program including savings card for eligible patients.","SYMBRAVO uses Axsome's patented MoSEIC technology; migraine affects ~40M Americans, 63% not satisfied with current treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156184,"accession_number":"0000950170-25-083793","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Axsome stockholders approve all four proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Roger A. Jeffs as Class I director with 27.3M votes for, 8.1M withheld.","Approved 2025 Long-Term Incentive Plan with 26.4M for, 8.9M against.","Ratified Deloitte & Touche as auditor for FY2025 with 40.8M for, 225.7K against.","Advisory say-on-pay passed with 34.8M for, 528.2K against.","Approximately 84% of shares (41.4M of 49.2M) represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156183,"accession_number":"0000950170-25-083441","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA refuses to file Axsome's NDA for AXS-14 (esreboxetine) for fibromyalgia; new trial required","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued RTF letter; second placebo-controlled trial deemed inadequate due to 8-week endpoint and flexible-dose design.","First trial (12-week, fixed-dose) accepted as adequate; both trials met primary endpoints with no efficacy concerns raised.","Axsome will conduct a new fixed-dose, 12-week trial; initiation expected in Q4 2025.","Delay extends approval timeline for potential treatment of ~17 million U.S. fibromyalgia patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156182,"accession_number":"0000950170-25-077374","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome settles SUNOSI patent litigation with Hetero; generic entry delayed until 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves patent litigation with Hetero over generic version of SUNOSI (solriamfetol).","Hetero licensed to sell generic SUNOSI on or after Sept 1, 2040 (if pediatric exclusivity) or March 1, 2040.","Settlement agreement subject to review by FTC and DOJ.","Similar patent litigation against other SUNOSI generic applicants remains pending in New Jersey court."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156181,"accession_number":"0000950170-25-069785","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Axsome enters $570M credit facility with Blackstone, retires Hercules loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $570M facility includes a $500M term loan (SOFR+4.75%) and a $70M revolver (SOFR+4.00%).","Initially drew $120M to repay existing Hercules term loan; up to $250M additional draws available at company's option.","Facility matures May 2030; 60-month interest-only period; expects significant reduction in interest expense.","Blackstone also purchased $15M of common stock at $107.14 per share in a concurrent private placement.","Company cites improved cost of capital and expanded credit capacity to support CNS pipeline growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156180,"accession_number":"0000950170-25-063158","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome Q1 total net product revenue $121.5M (+62% YoY); SYMBRAVO launch on track for June 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $121.5M (+62% YoY); AUVELITY $96.2M (+80%) and SUNOSI $25.2M (+17%).","Net loss improved to $59.4M ($1.22/sh) from $68.4M ($1.44/sh) in Q1 2024; includes $23.3M stock comp.","SYMBRAVO approved for acute migraine; commercial launch on track for June 2025.","NDA submitted for AXS-14 (fibromyalgia); sNDA for AXS-05 (AD agitation) on track for Q3 2025; AXS-12 (narcolepsy) NDA in H2 2025.","Cash $300.9M; company believes sufficient to fund operations to cash flow positivity."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":121463000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156179,"accession_number":"0000950170-25-048036","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome's solriamfetol misses primary endpoint in Phase 3 MDD trial; subgroup with severe EDS shows improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint (change in MADRS total score) not met in overall MDD population.","In prespecified subgroup with severe EDS (ESS ≥16), solriamfetol showed greater improvements vs placebo on multiple measures.","Axsome plans to initiate a Phase 3 trial in MDD with EDS in 2025 based on subgroup results.","Safety profile consistent with established safety of solriamfetol; no new signals.","Approximately 50% of MDD patients experience EDS, highlighting unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174633,"accession_number":"0000950170-25-044096","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome solriamfetol Phase 3 ADHD trial meets primary endpoint (p=0.039)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AISRS total score reduced 17.7 pts vs 14.3 for placebo at Week 6 (p=0.039) with 150 mg dose.","Key secondary endpoint CGI-S severity score also significant (p=0.017) for 150 mg solriamfetol.","53.5% of 150 mg patients achieved clinical response (≥30% AISRS reduction) vs 41.3% placebo (p=0.024).","Onset of improvement observed as early as Week 1 (p=0.036) vs placebo.","Company plans to initiate pediatric ADHD trial in 2025; safety profile consistent with prior studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174632,"accession_number":"0000950170-25-033064","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome settles Sunosi patent litigation with Hikma; generic entry deferred to 2040","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Hikma resolves patent litigation over Sunosi (solriamfetol) generic.","License for Hikma's generic Sunosi begins Sept 1, 2040 (with pediatric exclusivity) or March 1, 2040 (without).","Agreement subject to FTC/DOJ review; other patent litigation against other parties remains pending.","Axsome retains exclusive Sunosi rights until at least 2040, protecting key product revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174631,"accession_number":"0000950170-25-030395","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome gets FDA support for AXS-05 sNDA in Alzheimer's agitation; filing planned 3Q 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA pre-NDA meeting minutes confirm existing data package supports supplemental NDA submission for AXS-05.","Axsome plans to submit sNDA in third quarter 2025 for AXS-05 to treat Alzheimer's disease agitation.","AXS-05 previously granted FDA Breakthrough Therapy designation for Alzheimer's agitation in June 2020.","Three positive Phase 3 efficacy trials (ADVANCE-1, ACCORD-1, ACCORD-2) all met primary endpoint on CMAI.","No deaths in AXS-05 patients; no increased risk of falls, sedation, or cognitive decline in long-term data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174630,"accession_number":"0000950170-25-021801","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome Q4/FY24 revenue $118.8M/$385.7M; Auvelity growth 124% YoY; Symbravo approved; pipeline NDA submissions on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue FY24 $385.7M (+88%); Q4 $118.8M (+66% YoY).","Auvelity net sales FY24 $291.4M (+124%); Q4 $92.6M (+89% YoY).","Symbravo approved Jan 30, 2025 for acute migraine; commercial launch in ~4 months.","Patent settlement with Teva extends Auvelity generic entry to 2038–2039; license with pediatric exclusivity.","AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy) NDA submissions on track for 2H 2025; AXS-14 NDA submission in 1Q 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":385693000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174629,"accession_number":"0000950170-25-016678","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome settles AUVELITY patent litigation with Teva; generic entry no earlier than 2038-2039","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement grants Teva license to sell generic AUVELITY starting Mar 31, 2039 (if pediatric exclusivity) or Sep 30, 2038 (if not).","All ongoing AUVELITY patent litigation in U.S. District Court for New Jersey will be terminated.","Agreement is subject to review by the U.S. FTC and U.S. Department of Justice.","CEO Herriot Tabuteau says settlement reflects strength of Axsome’s IP portfolio and commitment to CNS innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174628,"accession_number":"0000950170-25-011220","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome receives FDA approval for SYMBRAVO (meloxicam/rizatriptan) for acute migraine in adults","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SYMBRAVO approved by FDA for acute treatment of migraine; expected commercially available in ~4 months.","In MOMENTUM trial, 77% of patients did not require rescue medication within 24h; superior to rizatriptan on sustained pain freedom.","In INTERCEPT trial (mild pain), 85% of patients did not require rescue medication within 24h; pain freedom sustained through 24-48h.","Most common adverse reactions: somnolence and dizziness (2% vs 1%). Long-term safety from MOVEMENT trial over 12 months.","Patented MoSEIC technology provides 5x faster meloxicam absorption; patent protection through at least 2040."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174627,"accession_number":"0000950170-25-004559","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome announces preliminary FY2024 revenue $385.2M; Auvelity $291.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product revenue Q4 $118.3M, full year $385.2M (unaudited preliminary).","Auvelity net product sales Q4 $92.6M, full year $291.4M.","Sunosi net product revenue Q4 $25.7M, full year $93.8M.","CEO cites positive Phase 3 results for AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy); regulatory filings planned in 2025.","Active launch preparations underway for AXS-07 (migraine), if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":385693000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191593,"accession_number":"0000950170-24-140949","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome AXS-05 succeeds in ACCORD-2 Phase 3 for Alzheimer's agitation; ADVANCE-2 misses primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ACCORD-2 met primary endpoint: time to relapse delayed (HR=0.276, p=0.001); 3.6-fold lower relapse risk vs placebo.","ADVANCE-2 did not reach statistical significance on primary endpoint (CMAI change: -13.8 vs -12.6, p=NS); results numerically favored AXS-05.","No deaths, no increased falls, sedation, or cognitive decline in any trial; long-term safety in >300 patients for 6 months.","Three of four pivotal Phase 3 trials now positive; company plans NDA submission to FDA in second half 2025.","AXS-05 holds Breakthrough Therapy designation for Alzheimer's disease agitation since June 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191592,"accession_number":"0000950170-24-130755","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome's AXS-12 meets primary endpoint in ENCORE Phase 3 trial for narcolepsy with cataplexy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: AXS-12 significantly reduced cataplexy attacks vs placebo (p=0.017); placebo worsening +10.29 attacks/week vs +1.32 with AXS-12.","Improvements in cognition and overall narcolepsy: NSAQ ability to concentrate (p=0.011) and PGI-C global improvement (p=0.024) both significant.","During open-label, 72% achieved ≥50% cataplexy reduction at 1 month, 82% at 6 months; mean ESS reduced 5.6 points at 1 month, 7.3 at 6 months.","Company plans to expedite NDA filing and request pre-NDA meeting with FDA; Orphan Drug Designation grants 7-year exclusivity upon approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191591,"accession_number":"0000950170-24-124546","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome Q3 revenue $104.8M (+81% YoY); Auvelity $80.4M (+113%); net loss $64.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $104.8M, up 81% YoY; Auvelity $80.4M (+113%), Sunosi $24.4M (+21%).","Net loss $64.6M ($1.34 loss per share); cash and equivalents $327.3M at Sept 30, 2024.","Auvelity sales force to expand to ~300 reps in Q1 2025 due to strong demand growth.","AXS-07 migraine NDA resubmission accepted with PDUFA goal date January 31, 2025.","Topline results for AXS-05 (AD agitation) and AXS-12 (narcolepsy) on track for Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":266927000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191590,"accession_number":"0000950170-24-110957","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Axsome amends Hercules loan: Tranche 3 raised to $80M, covenants eased","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fifth Amendment increases Tranche 3 commitment from $75M to $80M.","Availability periods extended: Tranche 1D to June 15, 2025; Tranche 1E to Dec 15, 2025.","Performance covenants restructured; new Performance Covenant D added.","Conditional waiver of $30M+ qualified cash requirement when market cap exceeds $1.5B.","Malta subsidiary permitted to request advances and hold more cash outside U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208062,"accession_number":"0000950170-24-103098","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Axsome's NDA resubmission for AXS-07 migraine treatment; PDUFA date Jan 31, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledged Class 2 resubmission of NDA for AXS-07 for acute migraine treatment.","PDUFA goal date set for January 31, 2025.","AXS-07 is a novel oral drug candidate for acute migraine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208061,"accession_number":"0000950170-24-099389","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome and Sandoz dismiss Sunosi patent litigation; Sandoz withdraws generic ANDA","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Sandoz withdrew its ANDA for a generic equivalent of Sunosi (solriamfetol), leading to dismissal of patent litigation without prejudice.","Litigation was pending in U.S. District Court for the District of New Jersey.","Dismissal removes a potential near-term generic threat to Sunosi, Axsome's CNS product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208060,"accession_number":"0000950170-24-090311","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Axsome Q2 revenue $87.2M (+87% YoY); Auvelity sales $65.0M (+135%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $87.2M, up 87% YoY; Auvelity $65.0M (+135%), Sunosi $22.1M (+16%).","Net loss $79.3M ($1.67 per share) vs $67.2M ($1.54) in Q2 2023; cash $315.7M.","NDA for AXS-07 in migraine resubmitted; NDA submission for AXS-14 in fibromyalgia expected Q3 2024.","Patent litigation with Unichem settled; generic Sunosi entry allowed no earlier than June 30, 2042.","Anticipated topline results: AXS-05 (AD agitation), solriamfetol (ADHD), AXS-12 (narcolepsy) in 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":162165000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225607,"accession_number":"0000950170-24-071960","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Axsome Therapeutics stockholders elect directors, ratify auditor, approve executive compensation at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Herriot Tabuteau (33.3M for, 0.5M withheld) and Mark Coleman (27.1M for, 6.7M withheld) as Class III directors.","Ratified Deloitte & Touche as independent auditor for FY2024 with 39.1M for, 0.15M against.","Advisory vote approved named executive officer compensation: 32.9M for, 0.87M against.","Approximately 84% of eligible shares (39.9M of 47.5M) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225606,"accession_number":"0000950170-24-069077","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome settles Sunosi patent litigation with Unichem; generic entry June 30, 2042","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves Hatch-Waxman litigation over Sunosi (solriamfetol) following Unichem's ANDA.","Unichem may begin selling generic Sunosi on June 30, 2042, subject to pediatric exclusivity extension.","Agreement subject to FTC and DOJ review; other Sunosi patent cases remain pending in New Jersey.","Axsome maintains Sunosi exclusivity until at least 2042 unless earlier triggering events occur."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225605,"accession_number":"0000950170-24-053197","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Axsome Q1 net product revenue $75M (+160% YoY); net loss $68.4M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Auvelity net sales $53.4M (+240% YoY); Sunosi net revenue $21.6M (+64% YoY).","Net loss $68.4M ($1.44/diluted share) vs $11.2M loss in Q1 2023 which included $62M one-time gain.","Cash $331.4M at March 31, 2024; company expects funds to support operations into cash flow positivity.","NDA resubmission for AXS-07 in migraine and NDA submission for AXS-14 in fibromyalgia targeted for Q2 2024.","Positive Phase 3 SYMPHONY trial of AXS-12 in narcolepsy; Phase 3 ACCORD-2 for AXS-05 in Alzheimer's agitation initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":74999000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225604,"accession_number":"0000950170-24-038894","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome initiates Phase 3 ENGAGE trial of solriamfetol for binge eating disorder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated ENGAGE Phase 3 trial of solriamfetol for binge eating disorder.","Trial is randomized, double-blind, placebo-controlled with ~450 patients.","Two doses (150 mg and 300 mg) vs placebo for 12 weeks; primary endpoint is change in binge eating episodes.","First patient screened in March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244775,"accession_number":"0000950170-24-035656","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome CRESCENDO survey: 77% of treated NT1 patients still have cataplexy; 74% cognitive impairment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["77% of treated NT1 patients continue to experience cataplexy attacks despite current therapy.","64% have excessive daytime sleepiness (ESS>10); 74% exhibit cognitive impairment (BC-CCI≥5).","Depression and anxiety reported by 45% and 57% of patients, respectively.","Survey included 203 adults; top treatments were wake-promoting agents (53%), oxybates (47%), stimulants (42%).","Axsome plans to present detailed CRESCENDO results at upcoming scientific meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244774,"accession_number":"0000950170-24-035655","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome Therapeutics Announces AXS-12 Meets Primary Endpoint in Phase 3 SYMPHONY Trial for Narcolepsy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AXS-12 reduced weekly cataplexy attacks by 83% vs 66% for placebo (p=0.018) at Week 5.","Cataplexy remission achieved by 33% of AXS-12 patients vs 9.5% placebo (p=0.008).","Excessive daytime sleepiness severity reduced (CGI-S p=0.027) and cognitive function improved (p=0.004).","Concurrent EDS and cataplexy response in 57% of AXS-12 patients vs 33% placebo (p=0.029)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244773,"accession_number":"0000950170-24-033148","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome doses first patient in PARADIGM Phase 3 trial of solriamfetol for MDD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 3 PARADIGM trial of solriamfetol for major depressive disorder.","Randomized, double-blind, placebo-controlled trial with ~300 patients (1:1 ratio, 300 mg or placebo for 6 weeks).","Primary endpoint is change in Montgomery-Åsberg Depression Rating Scale (MADRS).","Solriamfetol is an investigational treatment; Axsome specializes in CNS disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244772,"accession_number":"0000950170-24-017174","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome Therapeutics updates corporate presentation on February 20, 2024","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted updated corporate presentation to its website on February 20, 2024.","Presentation filed as Exhibit 99.1; specific content not available in filing text.","No financial results, clinical updates, or guidance changes disclosed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244771,"accession_number":"0000950170-24-016797","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Axsome Q4 2023 net product revenue $71.5M (+193% YoY); net loss $98.7M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $71.5M in Q4 2023 (+193% YoY); full year $204.9M (+309% YoY).","Auvelity net sales $49.0M in Q4 ($130.1M FY); Sunosi $22.5M Q4 ($74.8M FY, +67% YoY).","Net loss Q4 $98.7M ($2.08/share) vs $61.2M loss in Q4 2022; FY loss $239.2M ($5.27/share).","NDA submissions for AXS-07 (migraine) and AXS-14 (fibromyalgia) expected 1H 2024; SYMPHONY topline Q1 2024.","Cash $386.2M at Dec 31, 2023, up from $200.8M; sufficient to fund ops into cash flow positivity."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":270600000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244770,"accession_number":"0000950170-24-002685","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome updates corporate presentation; no financial details disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Axsome Therapeutics filed an 8-K on Jan 8, 2024, to announce an updated corporate presentation.","The presentation was posted to the company's website and filed as Exhibit 99.1.","No specific content, financial results, or guidance were provided in the filing.","Investors should refer to the full presentation on Axsome's website for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244769,"accession_number":"0000950170-24-001488","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Axsome reports preliminary Q4 net product revenue of $71M; full year $204M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary total net product revenue: $71M for Q4 2023, $204M for full year 2023.","Auvelity net sales: $49M Q4, $130M FY; Sunosi net revenue: $22M Q4, $74M FY.","2024 regulatory milestones: NDA submission for AXS-14 (fibromyalgia) Q1; NDA resubmission for AXS-07 (migraine) H1.","2024 clinical readouts: Phase 3 SYMPHONY (narcolepsy) Q1, ADVANCE-2 (Alzheimer's agitation) H1, FOCUS (ADHD) H2.","2024 trial initiations: Phase 3 solriamfetol for MDD, BED, SWD Q1; Phase 2/3 AXS-05 for smoking cessation."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":270600000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262212,"accession_number":"0000950170-23-068798","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Axsome hosts solriamfetol investor day with expert panel covering MDD, ADHD, BED, and sleep disorders","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Virtual investor event held Dec 7, 2023, featuring five physician thought leaders discussing solriamfetol.","Indications covered: MDD, ADHD, binge eating disorder, OSA/EDS (SHARP study), and shift work disorder.","Axsome management provided overview of clinical development plans for solriamfetol.","No specific clinical data, financial results, or pipeline milestones disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262211,"accession_number":"0000950170-23-059008","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Axsome Q3 product revenue $57.8M (up 244% YoY); Auvelity sales $37.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 product revenue was $57.8M vs $16.8M in Q3 2022; Auvelity net sales $37.7M (36% sequential growth).","Sunosi net product revenue $20.1M, up 20% YoY; total net loss of $62.2M ($1.32 per share) vs $44.8M loss in Q3 2022.","Cash and equivalents of $416.6M at Sept 30, 2023; shares outstanding 47.3M.","Pipeline on track: AXS-12 narcolepsy Phase 3 top-line expected Q1 2024; AXS-07 migraine NDA resubmission and AXS-14 fibromyalgia NDA submission both targeted H1 2024.","Auvelity sales force expanding from 162 to 260 representatives; payer coverage ~70% of covered lives."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":199070000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262210,"accession_number":"0000950170-23-052940","cik":1579428,"company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Axsome Therapeutics appoints Dr. Susan Mahony to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 4 to 5 directors; Dr. Mahony appointed effective Oct. 10, 2023.","Former Horizon Therapeutics board member and ex-SVP/President of Lilly Oncology.","Received initial option grant worth $325,000 vesting over 3 years and a pro-rated grant of $81,250 vesting in 1 year.","Annual cash retainer for non-employee directors, pro-rated for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12127008767.750212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-10-11T23:59:59+00:00|262210"}